title: Re-resection rates and risk characteristics following breast conserving surgery for breast cancer and carcinoma in situ: A single-centre study of 1575 consecutive cases.
abstract: OBJECTIVE
  To examine the frequency of re-resections and describe risk characteristics: invasive carcinoma or carcinoma in situ (CIS), palpability of the lesion, and neoadjuvant chemotherapy.
  
  
  RESULTS
  1703 breast conserving surgeries were performed: 1575 primary breast conserving surgeries (BCS), and 128 diagnostic excisions (DE). 176 BCS (11.2% [9.6; 12.7]) and 100 DE had inadequate margins indicating re-resection. The overall re-resection rate was 16.2% [14.5; 18.0]. 10.3% of invasive carcinoma BCS patients, and 28.6% CIS patients underwent re-resection (relative risk (RR) 2.8 [1.9; 4.1]). Invasive lobular carcinoma (ilc) had an RR of re-resection of 2.5 [1.7; 3.8], compared with invasive ductal carcinoma (idc).
  
  
  CONCLUSIONS
  Overall 11.2% of the BCS patients needed a re-resection. For isolated CIS (28.6%), RR of re-resection was almost three times as high compared to invasive carcinoma (10.3%). Ilc had an RR of re-resection of 2.5 compared to idc. Palpability and neoadjuvant chemotherapy did not significantly influence the risk of re-resection.
authors.affiliation: Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: c.kryh@hotmail.com.
authors.forename: C G
authors.initials: CG
authors.lastname: Kryh
authors.affiliation: Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: cpietersen@yahoo.com.
authors.forename: C A
authors.initials: CA
authors.lastname: Pietersen
authors.affiliation: Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: hans.rahr@slb.regionsyddanmark.dk.
authors.forename: H B
authors.initials: HB
authors.lastname: Rahr
authors.affiliation: Research Unit of General Practice, J.B. Winsloews Vej 9, 5000 Odense C, Denmark. Electronic address: depont42@gmail.com.
authors.forename: R D
authors.initials: RD
authors.lastname: Christensen
authors.affiliation: Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: peter.arne.wamberg@region.syddanmark.dk.
authors.forename: P
authors.initials: P
authors.lastname: Wamberg
authors.affiliation: Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: marianne.korsgaard@dadlnet.dk.
authors.forename: M D
authors.initials: MD
authors.lastname: Lautrup
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery*; D002278:Carcinoma in Situ / Q000473:pathology / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000473:pathology / Q000601:surgery*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000473:pathology / Q000601:surgery*; D018275:Carcinoma, Lobular / Q000473:pathology / Q000601:surgery*; D015331:Cohort Studies; D003718:Denmark; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D020360:Neoadjuvant Therapy; D012086:Reoperation; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents
keywords: Breast cancer; Carcinoma in situ; Invasive carcinoma; Neoadjuvant chemotherapy; Palpability; Re-resection